Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Non-Squamous Non-Small Cell Lung Cancer 2Neoplasms 2Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma 1

Interventions

pembrolizumab 181Gemcitabine 168Paclitaxel 150Carboplatin 135Bevacizumab 126Cisplatin 114Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 93Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 67Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 51Doxorubicin 50atezolizumab 48trametinib 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasms × imgatuzumab × Clear all
NCT04985825 2022-09-13

I-PACE

Centessa Pharmaceuticals plc

Phase 2 Withdrawn
Tumor-Agnostic

Carcinoma, Neoplasms

NCT00721266 2016-11-02

A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors.

Hoffmann-La Roche

Phase 1 Completed
102 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡